Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency.
In a single-blind, placebo-controlled study, the effects of a 3-month oral administration of 160 mg/day testosterone undecanoate (Andriol) on the quality of life of men with testosterone deficiency were evaluated. The subjects included ten men with primary hypogonadism and 29 with andropause with sexual dysfunction as the most common problem. The changes in subjective symptoms were evaluated by the PNUH QoL scoring system and the St. Louis University Questionnaire for androgen deficiency in aging males (ADAM). Digital rectal examination (DRE) was performed and serum testosterone, prostate-specific antigen (PSA) and liver profile were monitored. Testosterone undecanoate treatment (n = 33) significantly improved sexual dysfunction and symptom scores of metabolic, cardiopulmonary, musculoskeletal and gastrointestinal functions compared to baseline and to placebo (n = 6). ADAM score also significantly improved after 3 months of treatment. Serum testosterone was significantly increased compared to pretreatment levels only in the testosterone undecanoate group. In the placebo group, no significant changes compared to baseline were found for testosterone levels and QoL questionnaires. No abnormal findings were detected on DRE or laboratory findings in either group. Adverse events, such as gastrointestinal problems and fatigue, were mild and self-limiting. It is concluded that androgen supplement therapy with oral testosterone undecanoate (Andriol) restores the quality of life through improvement of general body functions in men with testosterone deficiency.
Park
N C
NC
Department of Urology, College of Medicine, Pusan National University, 1-10, Ami-dong, Seo-Ku, Pusan, 602-730, South Korea.
Yan
B Q
BQ
Chung
J M
JM
Lee
K M
KM
D000284:Administration, Oral; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy* / Q000523:psychology; D008297:Male; D011788:Quality of Life; D016037:Single-Blind Method; D013739:Testosterone / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000172:deficiency*; D045165:Testosterone Congeners / Q000008:administration & dosage*
D045165:Testosterone Congeners; D013739:Testosterone; C010792:testosterone undecanoate